Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M

Entrada Therapeutics, Inc.

Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.
Statistically significant improvement in Time to Rise velocity versus placebo (p<.05), 3.5x MCID threshold.
Dystrophin increased 2.36% over 4.00% baseline; exon skipping increased 2.31% over 2.66% baseline.
Cash, cash equivalents and marketable securities $254.9M as of March 31, 2026; runway into Q3 2027.
Q1 net loss $39.7M vs $17.3M in Q1 2025; collaboration revenue dropped to $0.9M from $20.6M.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.